Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study☆

[1]  Jagmeet P. Singh,et al.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.

[2]  J. Vessey,et al.  The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.

[3]  N. Weissman,et al.  An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.

[4]  J. Panza,et al.  Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. , 2001, JAMA.

[5]  D. Levy,et al.  Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). , 1996, The American journal of cardiology.

[6]  B. Howard,et al.  Prevalence and correlates of aortic regurgitation in American Indians: the Strong Heart Study. , 2000, Journal of the American College of Cardiology.

[7]  D. Bowen,et al.  Echocardiographic examination of women previously treated with fenfluramine: long-term follow-up of a randomized, double-blind, placebo-controlled trial. , 2001, Archives of internal medicine.

[8]  J. Burke,et al.  Prevalence of aortic regurgitation by color flow Doppler in relation to aortic root size. , 1990, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[9]  R. Rothman,et al.  Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin. , 2000, The American journal of cardiology.

[10]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[11]  M. Yacoub,et al.  Expression of 5-hydroxytryptamine receptor subtype messenger RNA in interstitial cells from human heart valves. , 2000, The Journal of heart valve disease.

[12]  B. Howard,et al.  Relations of left ventricular mass to demographic and hemodynamic variables in American Indians: the Strong Heart Study. , 1997, Circulation.

[13]  L. Weinrauch,et al.  A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[14]  R. Virmani,et al.  Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. , 1991, The American journal of pathology.

[15]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[16]  T. Najarian,et al.  Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. , 1999, Circulation.

[17]  J. Gardin,et al.  Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. , 2000, JAMA.

[18]  S. Erban,et al.  Risk for Valvular Heart Disease among Users of Fenfluramine and Dexfenfluramine Who Underwent Echocardiography before Use of Medication , 1998, Annals of Internal Medicine.

[19]  R. Devereux,et al.  Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. , 1999, Journal of the American College of Cardiology.

[20]  R. Devereux.  Appetite suppressants and valvular heart disease. , 1998, The New England journal of medicine.

[21]  B V Howard,et al.  Prevalence and correlates of mitral regurgitation in a population-based sample (the Strong Heart Study). , 2001, The American journal of cardiology.

[22]  D. Arnett,et al.  Aortic Root Dilatation at Sinuses of Valsalva and Aortic Regurgitation in Hypertensive and Normotensive Subjects: The Hypertension Genetic Epidemiology Network Study , 2001, Hypertension.

[23]  T. Ryan,et al.  Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. , 2000, Circulation.

[24]  M A Province,et al.  NHLBI family blood pressure program: methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network. , 2000, Annals of epidemiology.

[25]  N. Weissman,et al.  In vivo mitral valve morphology and motion in mitral valve prolapse. , 1994, The American journal of cardiology.

[26]  D. Levy,et al.  Determinants of echocardiographic aortic root size. The Framingham Heart Study. , 1995, Circulation.

[27]  R. Devereux,et al.  Two-dimensional echocardiographic aortic root dimensions in normal children and adults. , 1989, The American journal of cardiology.

[28]  A. Burger,et al.  Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. , 1999, Journal of the American College of Cardiology.

[29]  R. Devereux,et al.  Effect of Type 2 Diabetes Mellitus on Left Ventricular Geometry and Systolic Function in Hypertensive Subjects: Hypertension Genetic Epidemiology Network (HyperGEN) Study , 2001, Circulation.

[30]  N. Nanda,et al.  Evaluation of valvular regurgitation by color Doppler. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  W. Edwards,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[32]  P. Kligfield,et al.  Aortic root dilatation as a cause of isolated, severe aortic regurgitation. Prevalence, clinical and echocardiographic patterns, and relation to left ventricular hypertrophy and function. , 1987, Annals of internal medicine.

[33]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[34]  N. Weissman,et al.  Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. , 1999, Journal of the American College of Cardiology.

[35]  M. Davies,et al.  The aetiology and course of isolated severe aortic regurgitation: a clinical, pathological, and echocardiographic study. , 1987, British heart journal.

[36]  J Benichou,et al.  Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.

[37]  R Gorlin,et al.  Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. , 1976, The American journal of cardiology.